{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:49:31Z","timestamp":1782953371625,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bmcl.2026.130694","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:14:13Z","timestamp":1779725653000},"page":"130694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chlorophenylpyrazolone derivatives as novel PD-L1-targeted inhibitors of the PD-1\/PD-L1 immune checkpoint"],"prefix":"10.1016","volume":"139","author":[{"given":"Fr\u00e9d\u00e9rique","family":"Klupsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Le Biannic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassiba","family":"El Bouazzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Magnez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Rivoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Thiroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Vergoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Quesnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Leleu-Chavain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bmcl.2026.130694_bb0005","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/S1470-2045(24)00212-2","article-title":"Interchangeability of immune checkpoint inhibitors: an urgent need for action","volume":"25","author":"Zietse","year":"2024","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130694_bb0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint Signaling and Cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130694_bb0015","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in Cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"10.1016\/j.bmcl.2026.130694_bb0020","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3389\/fimmu.2020.01508","article-title":"Clinical and recent patents applications of PD-1\/PD-L1 targeting immunotherapy in Cancer treatment-current Progress, strategy, and future perspective","volume":"11","author":"Guo","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130694_bb0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2220\/biomedres.40.243","article-title":"Antitumor activity of the PD-1\/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse","volume":"40","author":"Ashizawa","year":"2019","journal-title":"Biomed Res"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130694_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"mAbs"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130694_bb0035","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/molecules24152804","article-title":"CA-170 \u2013 a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"issue":"42","key":"10.1016\/j.bmcl.2026.130694_bb0040","doi-asserted-by":"crossref","first-page":"72167","DOI":"10.18632\/oncotarget.20050","article-title":"Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130694_bb0045","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1021\/acs.jmedchem.0c00574","article-title":"Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell Death-1\/programmed cell death-ligand 1 interaction as potential anticancer agents","volume":"63","author":"Cheng","year":"2020","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130694_bb0050","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.1c00010","article-title":"Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell Death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130694_bb0055","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the PD-1\/PD-L1 Axis that promote PD-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130694_bb0060","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","article-title":"Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell Death-1\/programmed death-ligand 1 protein-protein interaction","volume":"62","author":"Basu","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130694_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118238","article-title":"Advances in Cancer immunotherapy using small-molecular inhibitors targeting the PD-1\/PD-L1 interaction","volume":"127","author":"Zhang","year":"2025","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130694_bb0070","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/acsmedchemlett.5c00245","article-title":"Characterization of clinically evaluated small-molecule inhibitors of PD-L1 for immunotherapy","volume":"16","author":"Slota","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130694_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114343","article-title":"Pyrazolones as inhibitors of immune checkpoint blocking the PD-1\/PD-L1 interaction","volume":"236","author":"Le Biannic","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"26","key":"10.1016\/j.bmcl.2026.130694_bb0080","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1002\/ejoc.201300380","article-title":"A convenient microwave-assisted Propylphosphonic anhydride (T3P\u00ae) mediated one-pot Pyrazolone synthesis","volume":"2013","author":"Desroses","year":"2013","journal-title":"Eur J Org Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130694_bb0085","doi-asserted-by":"crossref","first-page":"17623","DOI":"10.1038\/s41598-017-17963-1","article-title":"PD-1\/PD-L1 binding studies using microscale thermophoresis","volume":"7","author":"Magnez","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130694_bb0090","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.3390\/molecules27103316","article-title":"Antioxidant properties and aldehyde reactivity of PD-L1 targeted aryl-Pyrazolone anticancer agents","volume":"27","author":"Leleu-Chavain","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130694_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083491","article-title":"Novel PD-L1-targeted phenyl-pyrazolone derivatives with antioxidant properties","volume":"28","author":"Regnault","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130694_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2567.1996.461532.x","article-title":"Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells","volume":"87","author":"Belani","year":"1996","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130694_bb0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed Death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.bmcl.2026.130694_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114042","article-title":"Flurbiprofen as a biphenyl scaffold for the Design of Small Molecules Binding to PD-L1 protein dimer","volume":"178","author":"Bailly","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130694_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113821","article-title":"Protein homodimer sequestration with small molecules: focus on PD-L1","volume":"174","author":"Bailly","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130694_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107362","article-title":"N-glycosylation and Ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: a molecular Modeling study","volume":"88","author":"Bailly","year":"2020","journal-title":"Comput Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:35:22Z","timestamp":1782952522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S0960894X26001617"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130694","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlorophenylpyrazolone derivatives as novel PD-L1-targeted inhibitors of the PD-1\/PD-L1 immune checkpoint","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130694"}}